Роль модификации гистонов и метилирования ДНК в развитии почечно-клеточных карцином
- Авторы: Кутлыева Л.Р.1, Гилязова И.Р.1, Хусаинова Р.И.1, Хуснутдинова Э.К.1
-
Учреждения:
- Институт биохимии и генетики Уфимского научного центра РАН, Уфа, Республика Башкортостан, РФ
- Выпуск: Том 10, № 3 (2012)
- Страницы: 59-76
- Раздел: Статьи
- URL: https://journals.rcsi.science/ecolgenet/article/view/5507
- DOI: https://doi.org/10.17816/ecogen10359-76
- ID: 5507
Цитировать
Полный текст
Аннотация
Эпигенетические механизмы регуляции генов играют ключевую роль в канцерогенезе. Обзор посвящен анализу современного состояния исследований таких эпигенетических факторов, как модификации гистонов, геномный импринтинг, метилирование ДНК, ассоциированных с возникновением и прогрессированием рака почки.
Об авторах
Лилия Разифовна Кутлыева
Институт биохимии и генетики Уфимского научного центра РАН, Уфа, Республика Башкортостан, РФ
Email: mingazovaliliya@mail.ru Ufa
Ирина Ришатовна Гилязова
Институт биохимии и генетики Уфимского научного центра РАН, Уфа, Республика Башкортостан, РФ
Email: gilyasova_irina@mail.ru Ufa
Рита Игоревна Хусаинова
Институт биохимии и генетики Уфимского научного центра РАН, Уфа, Республика Башкортостан, РФ
Email: ritakh@mail.ru
Эльза Камилевна Хуснутдинова
Институт биохимии и генетики Уфимского научного центра РАН, Уфа, Республика Башкортостан, РФ
Email: ekkh@anrb.ru
Список литературы
- Гранов А. М., Якубович Е. И., Лавникевич Д. М. и др., 2008. Гендерные различия в метилировании 5'-фланкирующей области гена DUSP9 у больных со светлоклеточной карциномой почки // Мед. акад. журнал. Т. 8. № 3. С. 55–61.
- Евдокимов А. А., Зиновьев В. В., Кузнецов В. В. и др., 2009. Конструирование олигонуклеотидных ингибиторов ДНК-метилтрансферазы I человека // Молекулярная биология. Т. 43, № 3. C. 455–463
- Курынин Р. В., Михайленко Д. С., Залетаев Д. В. и др., 2008. Молекулярные маркеры в диагностике и лечении рака почки // Молекулярная медицина. № 4. С. 24–28.
- Лебедев И. Н., Саженова Е. А., 2008. Эпимутации импринтированных генов в геноме человека: классификация, причины возникновения, связь с наследственной патологией // Генетика. Т. 44. № 10. С. 1356–1373.
- Лихтенштейн А. В., Киселева Н. П., 2001. Метилирование ДНК и канцерогенез // Биохимия. № 66. C. 293–317.
- Логинов В. И., Ходырев Д. С., Пронина И. В. и др., 2009. Два СpG-островка гена SEMA3B: метилирование при светлоклеточном раке почки // Молекулярная биология. № 6. С. 1088–1092.
- Михайленко Д. С., Немцова М. В., 2007. Молекулярно-генетические маркеры рака почки // Российский онкологический журнал. № 4. С. 48–51.
- Назаренко С. А., 2002. Эпигенетическая регуляция активности генов и ее эволюция // Эволюционная биология. Материалы II Международной конференции «Проблема вида и видообразование». Томск: Томский государственный университет. Т. 2. C. 412.
- Пальцев М. А., Залетаев Д. В., 2009. Системы генетических и эпигенетических маркеров в диагностике онкологических заболеваний. М.: Медицина. С. 384.
- Смирнихина С. А., Лавров А. В., 2009. Методы оценки метилирования остатков цитозина в ДНК //Молекулярная биология. Т. 43. № 3. С. 474–479.
- Стрельников В. В., Кузнецова Е. Б., Танас А. А., 2010. Методы анализа метилирования ДНК // Введение в молекулярную диагностику / под ред. М. А. Пальцева. Москва, ОАО Издательство «Медицина». C. 368.
- Ahmad S. T., Arjumand W., Seth A., Saini A. K. et al., 2011. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population // Tumour Biol. (Epub ahead of print)
- Arita K., Ariyoshi M., Tochio H. et al., 2008. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism // Nature. Vol. 455. P. 818–821.
- Awakura Y., Nakamura E., Kamoto T. et al., 2008. Methylation-associated silencing of SFRP1 in renal cell carcinoma // Oncology Reports. Vol. 20. P. 1257–1263.
- Bannister A. J., Schneider R., Myers F. A. et al., 2005. Spatial distribution of di-and tri-methyl lysine 36 of histone H3 at active genes // J. Biol. Chem. Vol. 280. P. 17732–17736.
- Bannister A. J., Schneider R., Kouzarides T., 2010. Histone methylation: dynamic or static? // Nat. Rev. Cancer. Vol. 10(7). P.457–469.
- Bártová E., Krejcí J., Harnicarová A. et al., 2008. Histone modifications and nuclear architecture: a review // J. Histochem. Cytochem. Vol. 56 (8). P. 711–21.
- Bouzinba-Segard H., Guais A., Francastel C., 2006. Accumulation of small murine minor satellite transcripts leads to impaired centromeric architecture and function // Proc Natl Acad Sci USA. Vol. 103. P. 8709–8714.
- Caldwell G., Jones C., Gensberg K. et al., 2004. The Wnt antagonist sFRP1 in colorectal tumorigenesis //Cancer Res. Vol. 64. P. 883–888.
- Cheng J. C., Matsen F. A., Gonzales F. A. et al., 2003. Inhibition of DNA methylation and reactivation of silenced genes by zebularine // J. Natl. Cancer Inst. Vol. 95. P. 399–409.
- Cheung H., Lee T., Rennert O. et al., 2009. DNA methylation of cancer genome // Birth Defects Research (Part C). Vol. 87. P. 335–350.
- Chi P., Allis C. D., Wang G. G. 2010. Covalent histone modifications — miswritten, misinterpreted and miserased in human cancers // Nat Rev Cancer. Vol. 10. P. 457–469.
- Christoph F., Weikert St., Kempkensteffen C. et al., 2006. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications // Clin. Cancer Res. Vol. 12
- Dahl E., Wiesmann F., Woenekhaus M. et al., 2007. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma // Oncogene. Vol. 26. P. 5680–5690.
- Dalgliesh G.L., Furge K., Greenman C. et al., 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes // Nature. Vol. 4639. P. 360–363.
- Di Lorenzo A., Bedford M.T., 2011. Histone arginine methylation // FEBS Lett. Vol. 585 (13). P. 2024–2031.
- Duns G., van den Berg E., van Duivenbode I. et al., 2010. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma // Cancer Res. Vol. 70. P. 4287–4291.
- El-Osta A., 2003. DNMT cooperativity — the developing links between methylation, chromatin structure and cancer // Bioessays. Vol. 25. P. 1071–1084.
- Esteve P., Chin H., Pradhan S., 2005. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. // Proc Natl Acad Sci USA. Vol. 102. P. 1000–1005.
- Fabbri M., Garzon R., Cimmino A. et al., 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B // Proc Natl Acad Sci USA. Vol. 104. P. 15805–15810.
- Fan T., Schmidtmann A., Xi S. et al., 2008. DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development // Epigenetics. Vol. 3. P. 134–142.
- Foltz G., Ryu G., Yoon J. et al., 2006. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma // Cancer Res. Vol. 66. P. 6665–6674.
- Gama-Sosa M. A., Slagel V. A., Trewyn R. W. et al., 1983. The 5-methylcytosine content of DNA from human tumors // Nucleic. Acids Res. Vol. 11. P. 6883–6894.
- Goll M. G., Bestor T. H., 2005 Eukaryotic cytosine methyltransferases // Ann. Rev. Biochem. Vol. 74. P. 481–514.
- Gonzalgo M., Yegnasubramanian S., Yan G. et al., 2004. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis // Clin. Cancer Res. Vol. 10. P. 7276–7283.
- Gowher H., Liebert K., Herman A., Xu G., 2005. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA- (cytosine-C5)-methyltransferases by Dnmt3L // J. Bid Chem. Vol. 280. P. 13 341–13 348.
- Huang J., Dorsey J., Chuikov S. et al., 2010. G9a and Glp methylate lysine 373 in the tumor suppressor p53 // J. Biol. Chem. Vol. 285. Р. 9636–9641.
- Ito Y., Koessler T., Ibrahim A. E. et al., 2008. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. // Hum. Mol. Genet. Vol. 17. P. 2633–2643.
- Jemal A., Bray F., Center M. M, Ferlay J. et al., 2011. Global cancer statistics. // CA Cancer J. Clin. Vol. 61(2). P. 69–90.
- Kato K., Maesawa C., Itabashi T. et al., 2009. DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer // Int. J. Oncol. Vol. 35. P. 467–476.
- Kawada Y., Nakamura M., Ishida E. et al., 2001. Aberrations of the p14 (ARF) and p16 (INK4a) genes in renal cell carcinomas // J. J. Cancer Res. Vol. 92. P. 1293–1299.
- Kawamoto K., Hirata H., Kikuno N. et al., 2008. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines // Int. J. Cancer. Vol. 123. P. 535–542.
- Kim J. K., Samaranayake M., Pradhan S., 2009. Epigenetic mechanisms in mammals // Cell Mol. Life Sci. Vol. 66. P. 596–612.
- Klose R.J, Zhang Y., 2007. Regulation of histone methylation by demethylimination and demethylation. //Nat. Rev. Mol. Cell Biol. Vol. 8 (4). P. 307–318.
- Kondo M., Suzuki H., Ueda R. et al., 1995. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers // Oncogene. Vol. 10. P. 1193–1198.
- Kurdistani S. K., 2011 Histone modifications in cancer biology and prognosis. Prog. Drug Res. 67. P. 91–106.
- Larkin J., Goh X. Y., Vetter M. et al., 2012. Epigenetic regulation in RCC: opportunities for therapeutic intervention? // Nat. Rev. Urol. Vol. 9 (3). P. 147–155.
- Lim J., Kim S., Gabrielson E., Park Y. B. et al., 2005. Activation of human cancer / testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation // Int. J. Cancer. Vol. 116. P. 200–206.
- Lujambio A., Calin G., Villanueva A. et al., 2008. A microRNA DNA methylation signature for human cancer metastasis // Proc. Natl. Acad. Sci. USA. Vol. 105. P. 13556–13561.
- Majid Sh., Dar A. A., Ahmad A. E. et al., 2009. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer // Carcinogenesis. Vol. 4. P. 662–670.
- Martin C., Zhang Y., 2005. The diverse functions of histone lysine methylation // Nat. Rev. Mol. Cell Biol. Vol. 6 (11). P. 838–849.
- Martinez-Garcia E., Licht J. D., 2010. Deregulation of H3K27 methylation in cancer // Nat. Genet. Vol. 42. P. 100–101.
- Moore L. E., Pfeiffer R. M., Poscablo C. et al., 2008. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study // Lancet Oncol. Vol. 9. P. 359–366.
- Morris M. R., Hesson L., Wagner K. et al., 2003. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma // Oncogene. Vol. 22. P. 6794–6801.
- Morris M. R., Ricketts C., Gentle D. et al., 2010. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma // Oncogene. Vol. 29. P. 2104–2117.
- Morris M. R., Ricketts C. J., Gertle D. et al., 2011. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma // Oncogene. Vol. 30. P. 1390–1401.
- Nakagawa T., Kanai Y., Ushijima S. et al., 2005. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas // J. Urol. Vol. 173. P. 243–246.
- Nonomura N., Nishimura K., Tsuneharu M. et al., 1997. Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma // Cancer Res. Vol. 57. P. 2575–2577.
- Ongenaert M., Van Neste L., De Mey et al., 2008. PubMeth: a cancer methylation database combining text-mining and expert annotation // Nucleic Acids Res. Vol. 36. P. 842–846.
- Paiva F., Duarte-Pereira S., Costa V. L. et al., 2010. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms // DNA Cell Biol. Vol. 30. P. 85–90.
- Park P. J., 2009. ChIP-seq: advantages and challenges of a maturing technology // Nat. Rev. Genet. Vol.10. P. 669–80.
- Poke F. S., Qadi A., Holloway A., 2010. Reversing aberrant methylation patterns in cancer // Current Medicinal Chemistry. Vol. 17. P. 1246–1254.
- Raj K., Mufti G. J., 2006. Azacytidine (Vidaza (®) in the treatment of myelodysplastic syndromes // Ther. Clin. Risk Manag. Vol. 2. P. 377–388.
- Ramsahoye B., Biniszkiewicz D., Lyko F. et al., 2000. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a // Proc. Natl. Acad. Sci USA. Vol. 97. P. 5237–5242.
- Reik W., Walter J., 2001 Genomic imprinting: parental influence on the genome // Nat. Rev. Genet. Vol. 2. P. 21–32.
- Ricketts C. J., Morris M. R., Gentle D., 2012. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma //Epigenetics. Vol. 7. P. 278–90.
- Robertson K., Ait-Si-Ali S., Yokochi T. et al., 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters // Nat. Genet. 2000. Vol. 25. P. 338–342.
- Roman-Gomez J., Jimenez-Velasco A., Agirre X. et al., 2005. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia // J. Clin. Oncol. Vol. 23. P. 7043–7049.
- Ronald F., Morris M., Gentle D. et al., 2009. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma // Molecular cancer. Vol. 8. P. 31.
- Ruthenburg A. J., Li H., Patel D. J. et al., 2007. Multivalent engagement of chromatin modifications by linked binding modules // Nat. Rev. Mol. Cell Biol. Vol. 12. P. 983–994.
- Saxonov S., Berg P., Brutlag D., 2006. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. // Proc. Natl. Acad. Sci. USA. Vol. 103. P. 1412–1417.
- Scelfo R. A., Schwienbacher C., Veronese A. et al., 2002. Loss of methylation at chromosome 11p15.5 is common in human adult tumors // Oncogene. Vol. 21. P. 2564–2572.
- Schulte J., Lim S., Scramm A. et al., 2009. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy // Cancer Res. Vol. 69. P. 2065–2071.
- Sims R. J. 3rd, Nishioka K., Reinberg D., 2003. Histone lysine methylation: a signature for chromatin function // Trends Genet. Vol. 19. P. 629–639.
- Stephens K. E., Miaskowski C. A., Levine J. D. et al., 2012. Epigenetic Regulation and Measurement of Epigenetic Changes // Biol. Res. Nurs.
- Suzuki K., Suzuki I., Leodolter A. et al., 2006. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage // Cancer Cell. Vol. 9. P. 199–207.
- Takai D., Gonzales F. A., Tsai Y. C. et al, 2001. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer // Hum. Mol. Genet. Vol. 10. P. 2619–2626.
- Tang S. H., Yang D. H., Huang W. et al., 2006. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population // Clin. Cancer Res. Vol. 12. P. 4171–4177.
- Van Haaften G., Dalgliesh G. L., Davies H. et al., 2009. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer // Nat. Genet. Vol. 41. P. 521–523.
- Varela I., Tarpey P., Raine K. et al., 2011. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma // Nature. Vol. 469. P. 539–542.
- Vidaurreta M., Maestro M., Sanz-Casla M. et al., 2008. Inactivation of p16 by CpG hypermethylation in renal cell carcinoma // Urologic Oncology: Seminars and Original Investigations. Vol. 26. P. 239–245.
- Wang Q., Williamson M., Bott S. et al., 2007. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer // Oncogene. 2007. Vol. 26. P. 6560–6565.
- Yamada Y., Jackson-Grusby L., Linhart H. et al., 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis // Proc Natl Acad Sci USA. Vol. 102. P. 13580–13585.
- Yanagawa N., Tamura G., Honda T., et al., 2004. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines // Clin. Cancer Res. 2004. Vol. 10. P. 2447–2451.
- Yehezkel S., Segev Y., Viegas-Pequignot E. et al., 2008. Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions // Hum. Mol. Genet. Vol. 17. P. 2776–2789.
- Yoo K. H., Park Y. K., Kim H. S. et al., 2010. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma // Pathology International. Vol. 60. P. 661–666.
- Zhang Q., Ying J., Li J. et al., 2010. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage // The J. of Urology. Vol. 184. P. 731–737.
- Zhao W., Liu H., Liu W. et al., 2006. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration // Int. J. Oncol. Vol. 28. P. 1081–1088.
- Zhou L., Cheng X., Connoly B. A. et al., 2002. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. // J. Mol. Biol. Vol. 321. P. 591–599.
- Zhu H., Geiman T. M., Xi S., Schmidtmann A. et al., 2006. Lsh is involved in de novo methylation of DNA. // EMBO J. Vol. 25. P. 335–345.
- Aravin A., Sachidanandam R., Bouc’his D. et al., 2008. A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice // Mol. Cell. Vol. 31. P. 785–799.
- Costa V., Henrique R., Ribeiro F. et al., 2007. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors // BMC Cancer. Vol. 7. P. 133.
- Stresemann C., Brueckner B., Musch T. et al., 2006. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines // Cancer Res. Vol. 66. P. 2794–2800.